Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer

Castration resistant prostate cancer has historically been considered chemotherapy insensitive. However, the approval of estramustine phosphate, mitoxantrone, and docetaxel, over the past few decades, has challenged this notion. Despite these advances, until recently, only docetaxel had been shown t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsao, Che-Kai, Seng, Sonia, Oh, William K., Galsky, Matthew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117627/
https://www.ncbi.nlm.nih.gov/pubmed/21695098
http://dx.doi.org/10.4137/CMO.S6566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117627/
https://www.ncbi.nlm.nih.gov/pubmed/21695098
http://dx.doi.org/10.4137/CMO.S6566

Ejemplares similares